Evidence map›Paper›PMID 39294473›Full record

ArticleThe EMBO journal2024

Acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates immune responses in sepsis.

Xue Li, Xiangrong Li, Pengpeng Huang, Facai Zhang, Juanjuan K Du, Ying Kong, Ziqiang Shao, Xinxing Wu, Weijiao Fan, Houquan Tao and 10 more

Abstract read
In one paragraph

Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Aspirin-Derived Salicyl-CoA Drives Histone Lysine Salicylation Regulated by CBP and SIRT2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. The histone deacetylase family in health and disease.Signal transduction and targeted therapy · 2026
    Review
  5. Review
  6. [Anti-inflammatory Mechanisms of Human Resistin Through Activation of Peroxisome Proliferator-Activated Receptor γ].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Macrophages: sentinels, warriors, and healers.Human molecular genetics · 2025
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Xue Li *Institute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China. snowlee@zju.edu.cn.ORCID http://orcid.org/0000-0002-4863-3400
Xiangrong Li *Institutes of Biomedical Sciences, Fudan University, Shanghai, China.ORCID http://orcid.org/0009-0008-5390-0455
Pengpeng HuangInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.ORCID http://orcid.org/0000-0003-2862-0298
Facai ZhangInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Juanjuan K DuInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Ying KongDepartment of Urology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Ziqiang ShaoInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Xinxing WuInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Weijiao FanInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Houquan TaoInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Chuanzan ZhouInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Yan ShaoInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Yanling JinInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Meihua YeInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Yan ChenInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Jong DengYantai Peninsular Cancer Center, Binzhou Medical University, Yantai, China.ORCID http://orcid.org/0000-0002-4489-7556
Jimin ShaoDepartment of Pathology and Pathophysiology, Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0003-4792-5433
Jicheng YueYantai Peninsular Cancer Center, Binzhou Medical University, Yantai, China.ORCID http://orcid.org/0000-0001-7573-9561
Xiaju ChengState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, and Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China. xjcheng@suda.edu.cn.ORCID http://orcid.org/0000-0002-0292-5213
Y Eugene ChinnInstitute of Clinical Medicine Research, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China. chinyue@suda.edu.cn.ORCID http://orcid.org/0000-0003-4962-1396

Funding

MOST | | Medical Science and Technology Project of Zhejiang Province ( ) 2024KY670MOST | National Natural Science Foundation of China (NSFC) 2018YFC1705505MOST | National Natural Science Foundation of China (NSFC) 81820108023MOST | National Natural Science Foundation of China (NSFC) 8192913MOST | National Natural Science Foundation of China (NSFC) 82030077Open Program of the State key Laboratroy of Radiation Medicine and Protection GZK12023025the Interdisciplinary Basic Frontier Innovation Program of Suzhou Medical College, Soochow University YXY2304036
6 · The paper itself

Abstract

Activation of the Toll-like receptor 4 (TLR4) by bacterial endotoxins in macrophages plays a crucial role in the pathogenesis of sepsis. However, the mechanism underlying TLR4 activation in macrophages is still not fully understood. Here, we reveal that upon lipopolysaccharide (LPS) stimulation, lysine acetyltransferase CBP is recruited to the TLR4 signalosome complex leading to increased acetylation of the TIR domains of the TLR4 signalosome. Acetylation of the TLR4 signalosome TIR domains significantly enhances signaling activation via NF-κB rather than IRF3 pathways. Induction of NF-κB signaling is responsible for gene expression changes leading to M1 macrophage polarization. In sepsis patients, significantly elevated TLR4-TIR acetylation is observed in CD16+ monocytes combined with elevated expression of M1 macrophage markers. Pharmacological inhibition of HDAC1, which deacetylates the TIR domains, or CBP play opposite roles in sepsis. Our findings highlight the important role of TLR4-TIR domain acetylation in the regulation of the immune responses in sepsis, and we propose this reversible acetylation of TLR4 signalosomes as a potential therapeutic target for M1 macrophages during the progression of sepsis.

Indexed as

LipopolysaccharidesMacrophagesMyeloid Differentiation Factor 88NF-kappa BSepsisSignal TransductionToll-Like Receptor 4AcetylationAnimalsHistone Deacetylase 1HumansMaleProtein DomainsHDAC1 protein, humanHistone Deacetylase 1LipopolysaccharidesMYD88 protein, humanMyeloid Differentiation Factor 88NF-kappa BTLR4 protein, humanToll-Like Receptor 4HDAC1 InhibitorMacrophageNF-κB Signaling PathwaySepsisTLR4-TIR Acetylation

Identifiers

PMID39294473
PMCPMC11535217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.